Home
Live Updates
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis : comparemela.com
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
LOS ALTOS, Calif., Dec. 18, 2023 -- Unicycive Therapeutics, Inc. , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced the enrollment of...
Related Keywords
United States ,
Shalabh Gupta ,
Nasdaq ,
Exchange Commission ,
Linkedin ,
Globenewswire Inc ,
Unicycive Therapeutics Inc ,
Company Or Unicycive ,
Reason Research ,
Youtube ,
Shire International Licensing ,
Oxylanthanum Carbonate ,
Chief Executive Officer ,
New Drug Application ,
End Stage Renal Disease ,
Private Securities Litigation Reform Act ,
Risk Factor ,
Annual Report ,
Markets ,
comparemela.com © 2020. All Rights Reserved.